Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting is taking place in Washington, D.C., and virtually from 13-15 October 2021. The world’s largest meeting dedicated solely to cancer immunotherapy brings together stakeholders across the field to share research breakthroughs and educational updates to improve outcomes for cancer patients.
VJHemOnc caught up with the presenters on new research studies and clinical trials. Move videos coming soon!
SITC 2021
In a recent interview, @zucenka (@VU_LT) discussed a study using a conditioning regimen of alkylating agents, cytarabine, cladribine, HMAs, & venetoclax (ARCHIVE) for upfront alloSCT in patients with poor-risk newly diagnosed or R/R AML or MDS-IB2.
Watch here: 👉…
ARCHIVE conditioning for upfront alloSCT in active AML and high-risk MDS-IB2
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the results of a stu...
twitter.com
🎥 @apwiita of @UCSF discusses emerging strategies to improve #CARTCell efficacy in #myeloma, including CRISPR-engineered CARs and dual-antigen targeting to overcome antigen escape:
👉 👈
#MMSM #MultipleMyeloma #HemOnc #ImmunoOnc #ASH25
Improving CAR T-cell efficacy in myeloma: CRISPR engineering and dual-antigen targeting
Arun Wiita, MD, PhD, University of California, San Francisco, CA, discusses emerging strategies to improve CAR T-cell ...
ow.ly
It was lovely to speak with Jacqueline Barrientos of @MountSinaiMiami at #ASH25 to hear about the disparities in access to frontline therapies in patients with CLL in the United States.🩸
Make sure to watch the interview here:
👉 👈
#CLLsm #Leusm… https://twitter.com/i/web/status/2017659271895208201
Drivers of racial and ethnic disparities in access to frontline CLL therapy in the US
Jacqueline Barrientos, MD, MS, Mount Sinai Medical Center, Miami Beach, FL, discusses the disparities in access to f...
ow.ly
To hear an overview of the ongoing PhII ALPHA3 study evaluating first-line consolidation with cema-cel in patients with LBCL who have detectable MRD by ctDNA after standard frontline treatment, watch our recent interview with John Burke by clicking here:
🎥 ➡️…
ALPHA3 study: first-line cema-cel consolidation for MRD-positive LBCL after standard therapy
John Burke, MD, Rocky Mountain Cancer Centers, Aurora, CO, shares an overview of the ongoing Phase II ALPHA3 study...
twitter.com
INCA033989, a novel mutant CALR-specific monoclonal antibody, was a hot topic in the field of MPNs at #ASH25, with promising early results in both #EssentialThrombocythemia & #Myelofibrosis.🩸
Hear more from @harrisoncn1 of @GSTTnhs:
🎥 👉
#MPNsm #HemOnc… https://twitter.com/i/web/status/2017289267865608331
Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF
Claire Harrison, MD, FRCP, FRCPath, Guy's and St Thomas' NHS Foundation Trust, London, UK, discusses the safety and ...
ow.ly
SITC 2021
The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting is taking place in Washington, D.C., and virtually from 13-15 October 2021. The world’s largest meeting dedicated solely to cancer immunotherapy brings together stakeholders across the field to share research breakthroughs and educational updates to improve outcomes for cancer patients.
VJHemOnc caught up with the presenters on new research studies and clinical trials. Move videos coming soon!
In a recent interview, @zucenka (@VU_LT) discussed a study using a conditioning regimen of alkylating agents, cytarabine, cladribine, HMAs, & venetoclax (ARCHIVE) for upfront alloSCT in patients with poor-risk newly diagnosed or R/R AML or MDS-IB2.
Watch here: 👉…
ARCHIVE conditioning for upfront alloSCT in active AML and high-risk MDS-IB2
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the results of a stu...
twitter.com
🎥 @apwiita of @UCSF discusses emerging strategies to improve #CARTCell efficacy in #myeloma, including CRISPR-engineered CARs and dual-antigen targeting to overcome antigen escape:
👉 👈
#MMSM #MultipleMyeloma #HemOnc #ImmunoOnc #ASH25
Improving CAR T-cell efficacy in myeloma: CRISPR engineering and dual-antigen targeting
Arun Wiita, MD, PhD, University of California, San Francisco, CA, discusses emerging strategies to improve CAR T-cell ...
ow.ly
It was lovely to speak with Jacqueline Barrientos of @MountSinaiMiami at #ASH25 to hear about the disparities in access to frontline therapies in patients with CLL in the United States.🩸
Make sure to watch the interview here:
👉 👈
#CLLsm #Leusm… https://twitter.com/i/web/status/2017659271895208201
Drivers of racial and ethnic disparities in access to frontline CLL therapy in the US
Jacqueline Barrientos, MD, MS, Mount Sinai Medical Center, Miami Beach, FL, discusses the disparities in access to f...
ow.ly
To hear an overview of the ongoing PhII ALPHA3 study evaluating first-line consolidation with cema-cel in patients with LBCL who have detectable MRD by ctDNA after standard frontline treatment, watch our recent interview with John Burke by clicking here:
🎥 ➡️…
ALPHA3 study: first-line cema-cel consolidation for MRD-positive LBCL after standard therapy
John Burke, MD, Rocky Mountain Cancer Centers, Aurora, CO, shares an overview of the ongoing Phase II ALPHA3 study...
twitter.com
INCA033989, a novel mutant CALR-specific monoclonal antibody, was a hot topic in the field of MPNs at #ASH25, with promising early results in both #EssentialThrombocythemia & #Myelofibrosis.🩸
Hear more from @harrisoncn1 of @GSTTnhs:
🎥 👉
#MPNsm #HemOnc… https://twitter.com/i/web/status/2017289267865608331
Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF
Claire Harrison, MD, FRCP, FRCPath, Guy's and St Thomas' NHS Foundation Trust, London, UK, discusses the safety and ...
ow.ly
